Skip to content
10-Q

Quarterly Report

VIKING THERAPEUTICS, INC. VKTX

0001193125-26-193315

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 15, 2026 116.11M sh
Shares Diluted Q1 2026 · Mar 31, 2026 115.57M sh
Shares Diluted Q1 2026 · Mar 31, 2025 112.07M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$113.98M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$52.33M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $118.12M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $165.81M
Stockholders Equity Q1 2026 · Mar 31, 2026 $501.92M
Stockholders Equity Q1 2026 · Dec 31, 2025 $639.06M
Current Liabilities Q1 2026 · Mar 31, 2026 $106.33M
Current Liabilities Q1 2026 · Dec 31, 2025 $76.67M
Total Liabilities Q1 2026 · Mar 31, 2026 $106.33M
Total Liabilities Q1 2026 · Dec 31, 2025 $76.67M
Current Assets Q1 2026 · Mar 31, 2026 $608.21M
Current Assets Q1 2026 · Dec 31, 2025 $715.6M
Total Assets Q1 2026 · Mar 31, 2026 $608.24M
Total Assets Q1 2026 · Dec 31, 2025 $715.73M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.37
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.41
Eps Basic Q1 2026 · Mar 31, 2026 −$1.37
Eps Basic Q1 2026 · Mar 31, 2025 −$0.41
Sga Expense Q1 2026 · Mar 31, 2026 $13.98M
Sga Expense Q1 2026 · Mar 31, 2025 $14.08M
Rd Expense Q1 2026 · Mar 31, 2026 $150.15M
Rd Expense Q1 2026 · Mar 31, 2025 $41.39M
Net Income Q1 2026 · Mar 31, 2026 −$158.33M
Net Income Q1 2026 · Mar 31, 2025 −$45.63M
Operating Income Q1 2026 · Mar 31, 2026 −$164.13M
Operating Income Q1 2026 · Mar 31, 2025 −$55.47M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $0